| Literature DB >> 21073749 |
Weihong Li1, Daxin Wang, Guohua Song, Chunxia Zuo, Xianfu Qiao, Shucun Qin.
Abstract
BACKGROUND: It is designed to investigate the effects of combination therapy of allicin and fenofibrate on the endothelial and liver functions in rats with hyperlipidemia.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21073749 PMCID: PMC2998504 DOI: 10.1186/1476-511X-9-131
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Serum lipids in rats before administration of medication
| Groups | n | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) |
|---|---|---|---|---|---|
| Normal control | 11 | 1.760 ± 0.305 | 0.501 ± 0.086 | 1.362 ± 0.143 | 0.245 ± 0.034 |
| Model control | 9 | 4. 929 ± 2.142 a | 0.922 ± 0.178a | 1.578 ± 0.173 a | 2.428 ± 0.513 a |
| Fenofibrate | 10 | 5.153 ± 2.668 a | 0.908 ± 0.228 a | 1.662 ± 0.141 a | 2.370 ± 0.539 a |
| Allicin | 10 | 4. 893 ± 2.105a | 0.948 ± 0.251 a | 1.626 ± 0.129a | 2.499 ± 0.489 a |
| Combination | 10 | 5.007 ± 2.377 a | 0.949 ± 0.241 a | 1.590 ± 0.149 a | 2.421 ± 0.460 a |
TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Values are means ± SD; a: Compared to Normal control, P < 0.01
Serum lipids and NO levels in rats at the end of 12 weeks treatment
| Groups | n | TC(mmol/L) | TG(mmol/L) | HDL-C(mmol/L) | LDL-C(mmol/L) | NO(μmol/L) |
|---|---|---|---|---|---|---|
| Normal control | 11 | 1.726 ± 0.199 | 0.519 ± 0.053 | 1.344 ± 0.109 | 0.252 ± 0.024 | 38.047 ± 3.604 |
| Model control | 9 | 10.592 ± 2.258 a | 1.789 ± 0.078a | 1.722 ± 0.092 a | 6.272 ± 0.552 a | 23.649 ± 4.875 a |
| Fenofibrate | 10 | 4.853 ± 0.670 ac | 0.668 ± 0.061 ac | 1.832 ± 0.065 ad | 2.370 ± 0.263 ac | 32.729 ± 2.906bc |
| Allicin | 10 | 5.183 ± 0.718ac | 0.738 ± 0.071 ac | 1.793 ± 0.051a | 3.049 ± 0.278 ace | 30.520 ± 3.194 ac |
| Combination | 10 | 4.307 ± 0.490 ac | 0.689 ± 0.060 ac | 1.829 ± 0.055 ad | 2.251 ± 0.367 ac | 33.019 ± 3.879bc |
TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; NO: nitric oxide; Values are means ± SD; a and b: Compared to Normal control, a P < 0.01, bP < 0.05; c and d: Compared to Model control, cP < 0.01, dP < 0.05; e: Compared to Fenofibrate, e P < 0.01
Serum ALT and AST levels in rats at the end of 12 week treatment
| Groups | n | ALT(U/L) | AST(U/L) |
|---|---|---|---|
| Normal control | 11 | 35.364 ± 2.730 | 81.546 ± 5.087 |
| Model control | 9 | 70.333 ± 3.500 a | 134.778 ± 4.790 a |
| Fenofibrate | 10 | 49.200 ± 4.022 ac | 102.100 ± 5.840 ac |
| Allicin | 10 | 41.500 ± 3.375 acd | 92.100 ± 5.763 acd |
| Combination | 10 | 42.100 ± 3.665 acd | 90.400 ± 8.343bcd |
ALT: alanine transferase; AST: aspartate transferase; Values are means ± SD; a and b: Compared to Normal control, aP < 0.01,bP < 0.05; c: Compared to Model control, P < 0.01; d: Compared to Fenofibrate, P < 0.01
Ach-induced vascular relaxation of aorta rings in rats at the end of 12 week treatment (%)
| Ach (mol/L) | Normal control | Model control | Fenofibrate | Allicin | Combination |
|---|---|---|---|---|---|
| 1 × 10-8 | 9.504 ± 3.361 | 4.894 ± 1.838a | 7.924 ± 3.095 | 7.727 ± 2.524 | 8.160 ± 2.661 |
| 5 × 10-8 | 29.501 ± 5.825 | 10.468 ± 4.811a | 19.967 ± 5.227ac | 21.199 ± 5.952bc | 24.344 ± 6.081c |
| 1 × 10-7 | 45.167 ± 6.798 | 21.421 ± 4.423a | 35.535 ± 5.401ac | 37.791 ± 6.251bc | 38.110 ± 4.599bc |
| 5 × 10-7 | 59.172 ± 5.920 | 28.409 ± 5.214a | 42.072 ± 6.291ac | 43.341 ± 3.877ac | 45.893 ± 5.357ac |
| 1 × 10-6 | 65.610 ± 4.660 | 33.799 ± 5.341a | 51.420 ± 5.638 ac | 50.197 ± 6.689 ac | 53.360 ± 5.938 ac |
| 5 × 10-6 | 78.351 ± 5.409 | 41.251 ± 4.535 a | 59.392 ± 5.384 ac | 57.945 ± 3.376 ac | 61.576 ± 3.600 ac |
| 1 × 10-5 | 84.039 ± 3.895 | 45.537 ± 4.862 a | 66.847 ± 5.710 ac | 64.017 ± 4.827 ac | 69.594 ± 4.474 ac |
| 5 × 10-5 | 86.903 ± 4.872 | 49.129 ± 5.366 a | 68.593 ± 4.449 ac | 67.532 ± 3.549 ac | 75.037 ± 5.364 acd |
| 1 × 10-4 | 89.075 ± 4.248 | 48.627 ± 4.031 a | 67.903 ± 4.853 ac | 67.182 ± 5.459 ac | 74.959 ± 4.344 acd |
Ach: Acetylcholine; Values are means ± SD; a and b: Compared to Normal control, aP < 0.01, bP < 0.05; c: Compared to Model control, P < 0.01; d: Compared to Fenofibrate, P < 0.05
Figure 1The liver tissue HE Staining with 100 folds of amplification in rats at the end of 12 week treatment. A: Normal control; B: Model control; C: Fenofibrate treatment; D: Allicin treatment; E: Combination treatment.